Symptomatic treatment in the fragile X–associated tremor/ataxia syndrome
- 13 June 2006
- journal article
- research article
- Published by Wiley in Movement Disorders
- Vol. 21 (10) , 1741-1744
- https://doi.org/10.1002/mds.21001
Abstract
There is no established treatment for the neurological features of the recently discovered fragile X–associated tremor/ataxia syndrome (FXTAS). Fifty‐six patients with FXTAS completed a questionnaire to determine whether any medications had been effective for neurological symptoms. Of 11 subjects with definite FXTAS, 8 (70%) were on medications for their neurological symptoms, whereas most subjects with possible or probable FXTAS, 31 (70%) of 45 subjects, were not on medications. Although no therapy was uniformly effective for intention tremor, ataxia, Parkinsonism, memory loss, or anxiety, some subjects with intention tremor or Parkinsonism reported improvement with medications frequently used in other movement disorders. Overall, all 22 subjects on medications reported improvement in one or more symptoms. Lack of insight, recall bias, and cognitive impairment may have resulted in an underestimation of the beneficial effect of medical therapy. This study suggests that patients with FXTAS can derive improvement from medication treatment for some of their symptoms. © 2006 Movement Disorder SocietyKeywords
This publication has 6 references indexed in Scilit:
- Population-based case-control study of cognitive function in essential tremorNeurology, 2006
- Dopamine transporter imaging study in parkinsonism occurring in fragile X premutation carriersNeurology, 2005
- Aging in Individuals With the FMR1 MutationAmerican Journal on Mental Retardation, 2004
- Fragile X Premutation Tremor/Ataxia Syndrome: Molecular, Clinical, and Neuroimaging CorrelatesAmerican Journal of Human Genetics, 2003
- Tremor/Ataxia syndrome in fragile X carrier malesMovement Disorders, 2002
- Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile XNeurology, 2001